Teachers Retirement System of The State of Kentucky Has $173,000 Holdings in AMAG Pharmaceuticals, Inc. (AMAG)

Teachers Retirement System of The State of Kentucky continued to hold its stake in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 9,400 shares of the specialty pharmaceutical company’s stock at the close of the second quarter. Teachers Retirement System of The State of Kentucky’s holdings in AMAG Pharmaceuticals were worth $173,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. State of Alaska Department of Revenue raised its position in AMAG Pharmaceuticals by 81.3% during the 2nd quarter. State of Alaska Department of Revenue now owns 6,871 shares of the specialty pharmaceutical company’s stock worth $126,000 after buying an additional 3,081 shares during the last quarter. Municipal Employees Retirement System of Michigan raised its position in AMAG Pharmaceuticals by 6.6% during the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 8,280 shares of the specialty pharmaceutical company’s stock worth $152,000 after buying an additional 510 shares during the last quarter. Sei Investments Co. raised its position in AMAG Pharmaceuticals by 29.5% during the 2nd quarter. Sei Investments Co. now owns 10,799 shares of the specialty pharmaceutical company’s stock worth $199,000 after buying an additional 2,457 shares during the last quarter. Karp Capital Management Corp purchased a new position in AMAG Pharmaceuticals during the 1st quarter worth $232,000. Finally, Louisiana State Employees Retirement System raised its position in AMAG Pharmaceuticals by 2.1% during the 2nd quarter. Louisiana State Employees Retirement System now owns 14,300 shares of the specialty pharmaceutical company’s stock worth $263,000 after buying an additional 300 shares during the last quarter.

A number of research firms have recently weighed in on AMAG. Zacks Investment Research cut shares of AMAG Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, October 24th. Janney Montgomery Scott reaffirmed a “hold” rating on shares of AMAG Pharmaceuticals in a research note on Monday, October 23rd. Piper Jaffray Companies began coverage on shares of AMAG Pharmaceuticals in a research note on Monday, October 23rd. They set a “neutral” rating and a $18.00 price target on the stock. Cantor Fitzgerald reaffirmed a “hold” rating and set a $21.00 price target on shares of AMAG Pharmaceuticals in a research note on Thursday, September 28th. Finally, Morgan Stanley began coverage on shares of AMAG Pharmaceuticals in a research note on Friday, September 8th. They set an “overweight” rating and a $26.00 price target on the stock. Three analysts have rated the stock with a sell rating, eleven have assigned a hold rating and three have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $25.83.

AMAG Pharmaceuticals, Inc. (NASDAQ AMAG) opened at 15.35 on Monday. The stock’s market capitalization is $541.67 million. AMAG Pharmaceuticals, Inc. has a 12-month low of $14.90 and a 12-month high of $36.83. The firm has a 50-day moving average of $18.05 and a 200-day moving average of $18.80.

AMAG Pharmaceuticals (NASDAQ:AMAG) last released its earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported ($0.40) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.58) by $0.18. AMAG Pharmaceuticals had a negative return on equity of 4.81% and a negative net margin of 7.58%. The company had revenue of $158.39 million for the quarter, compared to analysts’ expectations of $158.83 million. During the same quarter in the previous year, the business posted $1.45 EPS. The business’s revenue for the quarter was up 24.3% on a year-over-year basis. Equities research analysts forecast that AMAG Pharmaceuticals, Inc. will post ($1.39) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This report was reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.com-unik.info/2017/10/30/teachers-retirement-system-of-the-state-of-kentucky-has-173000-holdings-in-amag-pharmaceuticals-inc-amag.html.

AMAG Pharmaceuticals Company Profile

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Institutional Ownership by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)

What are top analysts saying about AMAG Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for AMAG Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit